Dupont Capital Management Corp boosted its position in AbbVie Inc. (NYSE:ABBV – Free Report) by 9.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 65,152 shares of the company’s stock after acquiring an additional 5,741 shares during the quarter. AbbVie accounts for 1.7% of Dupont Capital Management Corp’s holdings, making the stock its 17th largest holding. Dupont Capital Management Corp’s holdings in AbbVie were worth $14,887,000 at the end of the most recent quarter.
A number of other hedge funds have also added to or reduced their stakes in ABBV. Wellington Management Group LLP increased its stake in AbbVie by 457.4% in the third quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock valued at $2,439,714,000 after acquiring an additional 8,646,424 shares during the last quarter. Raymond James Financial Inc. increased its stake in AbbVie by 41.8% in the second quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company’s stock valued at $1,733,222,000 after acquiring an additional 2,753,312 shares during the last quarter. Alliancebernstein L.P. increased its stake in AbbVie by 31.8% in the third quarter. Alliancebernstein L.P. now owns 7,281,327 shares of the company’s stock valued at $1,685,918,000 after acquiring an additional 1,758,657 shares during the last quarter. Amundi increased its stake in AbbVie by 15.6% in the third quarter. Amundi now owns 10,508,317 shares of the company’s stock valued at $2,418,909,000 after acquiring an additional 1,414,621 shares during the last quarter. Finally, Danske Bank A S bought a new position in AbbVie in the third quarter valued at approximately $279,609,000. 70.23% of the stock is owned by institutional investors.
AbbVie Stock Up 0.3%
Shares of AbbVie stock opened at $209.00 on Friday. AbbVie Inc. has a twelve month low of $168.54 and a twelve month high of $244.81. The stock has a market cap of $369.55 billion, a price-to-earnings ratio of 88.56, a P/E/G ratio of 0.74 and a beta of 0.38. The company’s fifty day moving average is $219.30 and its 200 day moving average is $223.67.
AbbVie Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.3%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s payout ratio is currently 293.22%.
Wall Street Analysts Forecast Growth
ABBV has been the topic of a number of recent analyst reports. BMO Capital Markets reissued an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. Barclays initiated coverage on shares of AbbVie in a research note on Thursday, February 19th. They issued an “overweight” rating and a $275.00 price objective on the stock. Berenberg Bank set a $275.00 price objective on shares of AbbVie in a research note on Tuesday, January 20th. Citigroup decreased their price objective on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 27th. Finally, Royal Bank Of Canada assumed coverage on shares of AbbVie in a research note on Tuesday, February 24th. They set an “outperform” rating and a $260.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $253.00.
Read Our Latest Stock Report on ABBV
Key Stories Impacting AbbVie
Here are the key news stories impacting AbbVie this week:
- Positive Sentiment: Motley Fool says ABBV is a “no‑brainer” buy on dips, highlighting its high dividend, cash flow and defensive pharma profile as reasons value/dividend investors should buy weakness. Why AbbVie Is a No-Brainer Stock to Buy on the Dip
- Positive Sentiment: AbbVie announced head‑to‑head Phase 4 psoriasis study updates — a potential near‑term clinical catalyst that could influence commercial positioning in immunology if results favor AbbVie’s therapy. AbbVie’s Head-to-Head Psoriasis Study Sets Up New Catalyst for ABBV Investors
- Positive Sentiment: AbbVie kicked off a Phase 1 trial for ABBV‑295 (obesity), signalling a strategic push into the high‑growth weight‑loss market where success could materially expand future revenue streams. AbbVie Steps Deeper Into Obesity Market With New Phase 1 ABBV-295 Trial
- Positive Sentiment: AbbVie paid an upfront of ~$650M to RemeGen for global rights to RC148 — a sizeable bolt‑on that strengthens the company’s oncology/rare disease pipeline (near‑term cash outflow but potential long‑term value). RemeGen Receives US$650 Million Upfront from AbbVie for RC148 Global Rights
- Neutral Sentiment: Evercore ISI trimmed its price target slightly ($233→$232) but kept an Outperform rating — a minor analyst tweak that maintains institutional conviction. Evercore ISI Tweaks AbbVie (ABBV) Estimates, Lowers Price Target Marginally
- Neutral Sentiment: Sector pieces and market reports (value stock roundups; thyroid‑eye‑disease market research) include AbbVie as a key player — these reinforce investor awareness but don’t move fundamentals immediately. 1 Value Stock Worth Your Attention and 2 That Underwhelm Thyroid Eye Disease Treatment Market Research Report 2026
- Negative Sentiment: Technicals are a headwind: the stock is trading below both the 50‑day and 200‑day moving averages, which can pressure short‑term sentiment and limit upside until price recovers those levels.
Insider Buying and Selling
In related news, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the transaction, the senior vice president directly owned 2,654 shares of the company’s stock, valued at $619,868.24. The trade was a 66.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the transaction, the executive vice president directly owned 38,137 shares in the company, valued at approximately $8,771,510. This represents a 36.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.06% of the stock is owned by insiders.
AbbVie Profile
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
See Also
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
